Sex based relative expression of estrogen receptors and tumor necrosis factor-alpha in liver affects hepatitis C virus viral pathogenesis

Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) is a global health concern, representing the second most common cause of malignancy-related mortality in the world. The primary cause of HCC in the United States is chronic infection with the hepatitis C virus (HCV). Clinical observations have established sex-based differences in HCV infection with the disease progressing more severely and more rapidly in males and postmenopausal females compared to premenopausal females, suggesting that estrogens and their receptors may play an important role in hepatic defenses and development of HCV-mediated HCC. However, the precise mechanism of estrogen protection and their effects on inflammation is poorly understood.

AIM

To determine whether estrogen receptor (ER) expression is correlated with the expression of tumor necrosis factor-alpha (TNF-α) in males and females with HCV-associated diseases.

METHODS

The role of ERs in modulating innate immune responses was investigated using human liver tissues with HCV/cirrhosis and HCV/HCC. Messenger RNA (mRNA) and protein (nuclear and cytoplasmic) expression were measured for all markers of interest and compared to normal human liver tissue samples.

RESULTS

ERβ was reported for the first time to have a greater mRNA expression than ERα in normal liver (P ≤ 0.001). In addition, ERβ mRNA expression was found to be decreased in diseased livers (P ≤ 0.05), while TNF-α expression was increased (P ≤ 0.0001). Upon stratifying by sex within each disease group, ESR1 was found to be negatively correlated with ESR2 in females with HCV/cirrhosis (r = -0.84, P ≤ 0.001), whereas males with HCV/cirrhosis were found to have a significant positive correlation (r = 0.57, P ≤ 0.05). ESR2 mRNA expression had a significant positive correlation with TNF-α in both HCV/cirrhosis (r = 0.61, P ≤ 0.001) and HCV/HCC patients (r = 0.45, P ≤ 0.05).

CONCLUSION

All together, these findings indicate that changes in ERβ and TNF-α expression are associated with worsening disease, and may be part of the sex-dependent factors in HCC pathogenesis.

Key Words: Hepatocellular carcinoma; Hepatitis C virus; Inflammation; Estrogen receptor; Liver cirrhosis; Tumor necrosis factor alpha

Core Tip: Our study, for the first time, demonstrates an increase in expression of estrogen receptor (ER) β compared to ERα in the liver of normal males and females. In addition, ERβ message RNA expression was found to be decreased in hepatitis C virus (HCV)/cirrhosis and HCV/hepatocellular carcinoma livers, while tumor necrosis factor-α expression was increased. Further analysis of the data revealed sex-specific correlations between ERα and ERβ. These findings suggest that changes in ERβ expression are associated with worsening HCV-related disease, and may be one of the sex-dependent factors in cirrhosis and hepatocellular carcinoma pathogenesis.

INTRODUCTION

Hepatocellular carcinoma (HCC) represents the second most common cause of malignancy related death in the world and its incidence is rapidly increasing, tripling in the last 4 decades[1]. In the United States alone, there are approximately 33000 new cases of HCC diagnosed per year, with 28000 people losing their life to HCC in that same time frame[2]. The most significant risk factor for development of HCC in the United States is chronic infection with hepatitis C virus (HCV)[1]. HCV is a global health concern that indiscriminately affects individuals in both underdeveloped and industrialized countries; over 2 million people in the United States alone are infected with the virus[3]. Persistent infection with HCV in the liver leads to a state of chronic inflammation, and over time can lead to problems such as fibrosis, cirrhosis, liver failure, and cancer, the most common of which is HCC[4]. HCV is a devastating cause of HCC worldwide, but especially in the United States where it represents the leading cause of HCC[1].

Interferon-based drug regimens were the foundation for HCV treatment for over 30 years, but are relatively unsuccessful at eliminating the virus and are associated with high rates of adverse side effects[4-6]. Direct-acting antivirals (DAAs) were developed in 2014 to address the shortcomings of interferon-based therapies; comparatively, DAAs have higher success rates and attenuated side effects[7]. Although the price of DAAs is decreasing as new drugs enter the market, a full treatment course can still range anywhere from 50000 Dollars to almost 100000 Dollars.

Due to the additional fact that there is currently no vaccine available for HCV, there is much interest in investigating host factors that can prevent or slow HCV-associated disease progression. Previous research has established that, compared to premenopausal females, both males and postmenopausal females are at a greater risk for developing HCV-associated diseases, and that their disease progression tends to be faster and more severe, suggesting that estrogens and their receptors may play an important role in HCV, and thereby progression to HCC[8-12].

Several epidemiological studies have reported that in females with HCV infection, lower circulating levels of estrogen are associated with a decreased response to treatment, increased expression of proinflammatory cytokines, more severe and faster rate of fibrosis, and greater risk of developing HCC[13-17]. Estrogen has also been shown to downregulate proinflammatory cytokine expression[18-20] and inhibit HCV entry and production[21-23], but, to date, causal factors linking estrogen to disease protection remain speculative. Estrogens exert their action primarily by activating nuclear estrogen receptors (ERs), of which there are two subtypes, ERα and ERβ. Previous studies in our lab have shown differential expression of ERα and ERβ in the livers of both males and females and across HCV-related disease severity[24]. Further, the diseased livers showed significantly higher expression of inflammatory marker nuclear factor kappa-B (NF-кB) and oncogenic marker cyclin D1. Given that HCV pathogenesis is almost entirely due to the ensuing chronic inflammation and not from cytotoxic factors from the virus itself, this paper reports the association between ERs and tumor necrosis factor-alpha (TNF-α) in HCV-infected subjects with cirrhosis and HCC.

TNF receptor 1 (TNFR1) plays the leading role in liver physiology[25]. TNF-α is a pleiotropic cytokine that is involved in a variety of functions in the liver such as proliferation, metabolic activation, inflammatory responses, and apoptosis. TNF-α facilitates the activation of several diverse signaling cascades, depending on its ligation to either TNFR1 or TNFR2. TNFR1 signaling can mediate the cleavage and activation of pro-apoptotic caspase-8; TNFR2 initiates the anti-apoptotic, pro-proliferative protein kinase B pathways[25,26]. Because TNF-α can initiate both cytoprotective and apoptotic responses, its role in HCV pathogenesis is unclear. Individuals with TNF-α genotypes that trigger increased production and secretion of TNF-α were associated with having an increased risk of fibrosis and cirrhosis[27], possibly due to the action of HCV proteins suppressing NF-кB activation and enhancing TNF-α-induced cell death[28].

Understanding the link between sex, ERs, and inflammation mediated by TNF-α during HCV pathogenesis will help identify new targets for therapy, further personalize treatment strategies, and recognize individuals who are at a higher risk for HCV-related HCC disease progression.

MATERIALS AND METHODS

Patients

Explant liver tissues from deidentified patients with end stage liver disease due to either HCV-related cirrhosis or HCV-related HCC were obtained from the National Institutes of Health Liver Tissue and Cell Distribution System (LTCDS) at the University of Minnesota, Minneapolis, MN, United States. Normal liver tissues from LTCDS with no diagnosis of HCV or HCC obtained from cadaver donor livers not used for transplantation were included as controls. Exclusion criteria for both study and control samples included patients co-infected with human immunodeficiency virus or hepatitis B virus or with a history of alcohol consumption or drug use. Liver explants were aseptically collected and snap frozen in liquid nitrogen and stored at -80 °C until further use. The study received approval from the Institutional Review Board at the University of Minnesota under Exemption IV. The study was conducted at Oklahoma State University Center for Health Sciences under exempt Institutional Review Board guidelines.

Quantitative analysis of message RNA expression

Total RNA was extracted from all human liver tissues using TRIzol reagent (Cat No. 15596026; Invitrogen) and cleaned using the QIAGEN RNeasy mini kit (Cat No. 74106) per the manufacturer protocol. Approximately 2 μg of total RNA was reverse transcribed using Moloney-Murine Leukemia Virus Reverse Transcriptase (Cat No. M1701; Promega) and random primers per the manufacturer protocol. Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was performed using custom primers from Invitrogen/Thermo Fisher Scientific. Reactions were carried out in triplicate with PowerUp SYBR Green Master Mix (Cat No. A25742; Applied Biosystems) on an Applied Biosystems 7500 real-time PCR system. Samples were analyzed using Applied Biosystems 7500 Software v.2.0.6. Relative differences in gene expression between groups were calculated using cycle threshold values (Ct). The expression of target genes in liver tissues was normalized to the expression of endogenous control genes beta-glucuronidase and serine and arginine-rich splicing factor 4[29-31]. The gene expression of the treatment group was further normalized to the experimental controls using the ΔΔCt method and expressed as fold change. Reaction efficiency for all targets was assessed to be 102.2% ± 4.0% (n = 2) by titrating samples and using the integrated tool of the Applied Biosystems software.

Analysis of protein expression

Protein concentrations were determined using the Pierce bicinchoninic acid protein assay kit (Cat No. 23225). Radio immunoprecipitation assay lysis buffer was used to prepare total protein extracts from cells. Representative liver tissues were selected from HCV/cirrhosis, HCV/HCC, and normal patient groups. Cytoplasmic, nuclear, and total protein fractions were prepared from liver tissues using the Thermo Fisher Scientific NE-PER Nuclear and Cytoplasmic Extraction Reagents (Cat No. 78833) or T-PER™ Tissue Protein Extraction Reagent (Cat No. 78510) as per the manufacturer’s instructions.

Equivalent protein (25-50 μg) per sample was loaded and separated on a 4%-12% gradient Bis-Tris polyacrylamide gels. Gels were then wet transferred to a nitrocellulose membrane, stained with REVERT total protein stain [Cat No. 926-11015; Odyssey CLx Near-Infrared Fluorescence Imaging System (LI-COR)] to verify complete transfer of proteins, and imaged for loading control. Blots were rinsed and blocked with intercept blocking buffer in the Bethesda system (Cat No. 927-60001, LI-COR). Blots were incubated overnight at 4 °C while shaking with the indicated primary antibody (Table 1). Blots were rinsed and incubated for 1 hour at room temperature while shaking with the appropriate secondary antibody. Blots were rinsed and imaged on a LI-COR. Image capture and densitometry were performed using Image Studio Lite v.5.2 software. Data were normalized to total protein[32,33]. Anti-histone H3 and anti-glyceraldehyde-3-phosphate dehydrogenase antibodies were used to confirm purity of cytoplasmic and nuclear fractions.

Table 1 Antibodies and positive controls used for western blot.

Antibody	Catalog	Host/class/isotype	Concentration	Observed size (kDa) in human liver
Anti-ERβ	Abcam; ab3576	Rabbit/polyclonal/IgG	1:1000; (1:30000 2nd)	70
Anti-TNF-α	Abcam; ab1793	Mouse/monoclonal/IgG1	1:1000; (1:10000 2nd)	45
Anti-ERα	Invitrogen; MA5-13191	Mouse/monoclonal/IgG1	1:500; (1:10000 2nd)	37
Anti-Histone H3	Abcam; ab1791	Rabbit/polyclonal/IgG	1:1000; (1:20000 2nd)	15
Anti-GAPDH (0411)	Santa Cruz; sc-47724	Mouse/monoclonal/IgG1	1:1000; (1:10000 2nd)	50
Anti-rabbit IRDye® 800CW	LI-COR; 926-32213	Donkey/IgG	Varies
Anti-mouse IRDye® 800CW	LI-COR; 926-32212	Donkey/IgG	Varies
Recombinant human TNF-α	Abcam; ab55237		10 ng/well	25

TNF-α: Tumor necrosis factor-alpha; ER: Estrogen receptor; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.

Statistical analysis

Data obtained from the experiments were analyzed statistically and graphed using GraphPad Prism version 10 (GraphPad Software Inc, La Jolla, CA, United States). Characteristics of the study population were compared using the χ² test. Statistical significance between appropriate groups in in vitro data was determined by parametric one-way analysis of variance, and post-hoc analyses were performed using Dunnett’s multiple comparisons test. Ex vivo data were analyzed using non-parametric methods that included the Kruskall-Wallis test and Mann Whitney U test; post-hoc analyses were performed using Dunn’s Multiple Comparison test. Correlations between ER subtype expression and expression of inflammatory markers in liver tissues were analyzed by using the Spearman’s rank correlation test. P ≤ 0.05 was considered statistically significant.

RESULTS

Study population

A total of 55 cases (HCV/cirrhosis, n = 32; HCV/HCC, n = 23) and 36 normal controls were included in the analyses. Cases and controls did not differ significantly in the distribution of age, sex, or race (Table 2). Normal and cirrhosis males were slightly younger than their female counterparts, whereas HCC females were, on average, 10 years older than HCC males (Table 3). However, the medians were not significantly different between the groups.

Table 2 Characteristics of the study population, mean ± SD.

Characteristics	Normal (n = 36)		Cirrhosis (n = 32)		HCC (n = 23)		P value
	n	(%)	n	(%)	n	(%)
Age (year)
< 49	10	(27.8)	12	(37.5)	6	(26.1)	0.2593
50-59	15	(41.7)	17	(53.1)	10	(43.5)
≥ 60	11	(30.6)	3	(9.4)	7	(30.4)
Mean age (year)	52.0 ± 14.6		52.2 ± 6.8		55.5 ± 7.1		0.3087
Sex
Male	18	(50.0)	17	(53.1)	18	(78.3)	0.0765
Female	18	(50.0)	15	(46.9)	5	(21.7)
Race
White	18	(50.0)	22	(68.8)	15	(65.2)	0.4398
African American	2	(5.6)	1	(3.1)	2	(8.7)
Other/Unknown	16	(44.4)	9	(28.1)	6	(26.1)
Mean AST (U/L)			187.6 ± 389.3		114.2 ± 62.4		0.4542
Mean ALP (U/L)			158.5 ± 150.1		189.3 ± 110.4		0.0369
Mean total bilirubin (mg/dL)			8.6 ± 11.7		2.8 ± 6.8		< 0.0001
Mean creatinine (mg/dL)			1.8 ± 1.5		2.1 ± 2.9		0.3134
IFNL4-ΔG genotype
TT/TT	11	(30.6)	11	(34.4)	7	(30.4)	0.8405
ΔG/TT	18	(50.0)	13	(40.6)	9	(39.1)
ΔG/ΔG	6	(16.7)	5	(15.6)	6	(26.1)
Undetermined	1	(2.8)	3	(9.4)	1	(4.3)
IFNL4-ΔG allele frequency (%)	42.9		39.7		47.7

HCC: Hepatocellular carcinoma; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase.

Table 3 Mean age of males and females in each disease group, mean ± SD.

	Mean age (year)			P value
	Normal	Cirrhosis	HCC
Male	50.8 ± 18.3	50.7 ± 5.0	53.3 ± 5.9	0.0716
Female	53.1 ± 10.4	54.0 ± 8.3	63.3 ± 5.1

HCC: Hepatocellular carcinoma.

Information regarding total bilirubin, creatinine, and liver enzymes aspartate aminotransferase (AST) and alkaline phosphatase (ALP) were available for most HCV/cirrhosis and HCV/HCC patients. AST and creatinine levels did not differ significantly between the groups, but ALP and total bilirubin levels were significantly different between HCV/cirrhosis and HCC groups (Table 2). When only HCV-positive samples were isolated and stratified by sex, males were found to have significantly higher levels of AST compared to females (Table 4).

Table 4 Clinical characteristics of hepatitis C virus-positive samples, by sex.

Characteristics	Female (n = 20)	Male (n = 35)	P value
Mean AST (U/L)	79.0 ± 44.7	213.8 ± 390.7	0.0186
Mean ALP (U/L)	158.3 ± 112.7	182.1 ± 156.5	0.4255
Mean total bilirubin (mg/dL)	4.8 ± 9.3	7.7 ± 11.6	0.3179
Mean creatinine (mg/dL)	1.4 ± 1.0	1.5 ± 1.0	0.6716

AST: Aspartate aminotransferase; ALP: Alkaline phosphatase.

Expression of ERβ is significantly higher than ERα in normal livers

To investigate the role of ERs in HCV-associated diseases, the message RNA (mRNA) expression of ERα and ERβ was first measured in normal livers using RT-qPCR. ESR2 expression levels were significantly higher than ESR1 levels when the data were pooled (Figure 1A) and when they were segregated by sex (Figure 1B). Since ERα and ERβ are known co-regulators of physiological outcomes, the ESR1/ESR2 expression ratio was compared between males and females and it was found to be comparable (Figure 1C).

Figure 1 Message RNA expression of estrogen receptor α and estrogen receptor β in human liver tissues from normal subjects. A: Estrogen receptor subtype expression was analyzed in human liver tissues by quantitative reverse transcription polymerase chain reaction using gene specific primers. Target gene expression was normalized to GUSB and SRSF4 expression using the ΔCt method and plotted; B: Stratification of A by sex; C: Ratio of ESR1 to ESR2 message RNA expression in normals stratified by sex. Column bars represent the median. Each symbol represents one individual. Data were analyzed by Mann-Whitney U or Kruskal-Wallis test where ^aP ≤ 0.05. ^bP ≤ 0.01. ^dP ≤ 0.0001. mRNA: Message RNA.

Expression of ERβ, but not ERα, is altered in patients with HCV-associated diseases

The expression of ER subtypes in HCV/cirrhosis and HCV/HCC liver explants was then measured and compared to normal using RT-qPCR and Western blotting. At the transcriptional level, there was an apparent increase in ESR1 expression in HCV/HCC livers, though the results were not statistically significant (Figure 2A and B). ERα protein expression decreased in HCV-related diseased livers, but again, the results were not statistically significant (Figure 2C-E).

Figure 2 Expression of estrogen receptor α in human liver tissues with hepatitis C virus-related diseases. Estrogen receptor (ER) α message RNA and protein expressions were analyzed in hepatitis C virus (HCV)-related cirrhosis and HCV-related hepatocellular carcinoma liver tissues and compared to normals. A: ESR1 transcript levels by quantitative reverse transcription polymerase chain reaction normalized to GUSB and SRSF4 expression and compared using the ΔΔCt method; B: Stratification of A by sex; C: ERα protein expression by Western blot using whole liver tissue lysates (tot); D: Quantification of C by densitometry from multiple blots and normalized to total protein; E: ERα protein expression in human liver tissues stratified by sex. Column bars represent the median. Each symbol represents one individual. Data were analyzed by Kruskal-Wallis test with Dunn’s Multiple Comparisons posttest where P ≤ 0.05 was considered significant. mRNA: Message RNA; HCC: Hepatocellular carcinoma; ER: Estrogen receptor; TPS: Total protein stain.

ESR2 mRNA expression was significantly lower in the HCV/HCC group as compared to normal (Figure 3). As expected, the ESR1/ESR2 ratio expression was significantly increased in HCV/HCC livers compared to normal (Figure 3). No significant differences in ESR2 expression or in ESR1/ESR2 ratio was found when results were stratified by both disease and sex (Figure 3). ESR1/ESR2 ratio in males with HCV/cirrhosis did show opposite trend of expression compared to females; however, it did not reach significance (Figure 3).

Figure 3 Message RNA expression of estrogen receptor β in human liver tissues with hepatitis C virus-related diseases. Estrogen receptor (ER) β message RNA (mRNA) expression was analyzed in hepatitis C virus (HCV)-related cirrhosis and HCV-related hepatocellular carcinoma liver tissues and compared to normals. A: ESR2 transcript levels by quantitative reverse transcription polymerase chain reaction normalized to GUSB and SRSF4 expression and compared using the ΔΔCt method; B: Stratification of A by sex; C: Ratio of ESR1 to ESR2 mRNA expression; D: Stratification of C by sex. Column bars represent the median. Each symbol represents one individual. Data were analyzed by Kruskal-Wallis test with Dunn’s Multiple Comparisons posttest where P ≤ 0.05 was considered significant. ^aP ≤ 0.05. mRNA: Message RNA; HCC: Hepatocellular carcinoma.

There was a significant increase in the liver protein expression of ERβ in HCV/cirrhosis and HCC as compared to normal in both nuclear and cytoplasmic fractions (Figure 4A-C). When results were stratified by sex, the increase in nuclear ERβ was only significant in cirrhosis females and the increase in cytoplasmic ERβ was only significant in HCC females (Figure 4D and E). Although no significant differences were found at the transcriptional level, at the translational level, when the ratio of ERα total protein expression to ERβ cytoplasmic protein expression was analyzed, there was a significant decrease in both HCV/cirrhosis and HCC subjects compared to normal (data not shown). These results suggest that HCV disease progression may alter the expression of ER subtypes, specifically ERβ.

Figure 4 Protein expression of estrogen receptor β in human liver tissues with hepatitis C virus-related diseases. Estrogen receptor (ER) β protein expression was analyzed in hepatitis C virus (HCV)-related cirrhosis and HCV-related hepatocellular carcinoma liver tissues and compared to normals. A: ERβ protein expression by Western blot in human liver tissues fractionated by nuclear and cytoplasmic protein; B and C: Quantification of A by densitometry from multiple blots and normalized to total protein; D and E: ERβ protein expression in nuclear and cytoplasmic fractions of human liver tissues and stratified by sex. Column bars represent the median. Each symbol represents one individual. Data were analyzed by Kruskal-Wallis test with Dunn’s Multiple Comparisons posttest where ^aP ≤ 0.05. ^bP ≤ 0.01. ^cP ≤ 0.001. Nuc: Nuclear; Cyt: Cytoplasmic; HCC: Hepatocellular carcinoma; ER: Estrogen receptor; TPS: Total protein stain.

TNF-α mRNA expression is increased in patients with HCV-associated diseases

Because HCV pathogenesis relies primarily on inflammation to cause damage, the expression of proinflammatory cytokine TNF-α in this cohort was analyzed. TNF-α mRNA expression was significantly increased in both HCV/cirrhosis and HCV/HCC groups compared to normal (Figure 5A). When results were stratified by sex, TNF-α expression was only significantly higher in HCV/cirrhosis livers of both males and females compared to normal (Figure 5B). Although the results were not statistically significant, TNF-α protein expression followed a similar trend as mRNA expression (Figure 5C-E).

Figure 5 Expression of tumor necrosis factor-alpha in human liver tissues with hepatitis C virus-related diseases. Tumor necrosis factor-alpha (TNF-α) message RNA and protein expressions were analyzed in hepatitis C virus (HCV)-related cirrhosis and HCV-related hepatocellular carcinoma liver tissues and compared to normals. A: TNF-α transcript levels by quantitative reverse transcription polymerase chain reaction normalized to GUSB and SRSF4 expression and compared using the ΔΔCt method; B: Stratification of A by sex; C: TNF-α protein expression by Western blot using whole liver tissue lysates; D: Quantification of C by densitometry from multiple blots and normalized to total protein; E: Stratification of D by sex. Column bars represent the median. Each symbol represents one individual. Data were analyzed by Kruskal-Wallis test with Dunn’s Multiple Comparisons posttest where ^aP ≤ 0.05. ^cP ≤ 0.001. TNF-α: Tumor necrosis factor-alpha; HCC: Hepatocellular carcinoma; TPS: Total protein stain.

Correlation analyses by disease

Spearman’s correlation coefficient was determined using RT-qPCR data from HCV/cirrhosis, HCV/HCC, and normal livers to compare the degree of association between the mRNA expression of ESR1, ESR2, ESR1/ESR2, and TNF-α (Table 5). Upon stratifying by sex within each disease group, ESR1 was found to be negatively correlated with ESR2 in females with HCV/cirrhosis (r = -0.84, P = 0.0002). Interestingly, males with HCV/cirrhosis were found to instead have a significant positive correlation between ESR1 and ESR2 (r = 0.57, P = 0.0197) (Table 5).

Table 5 Spearman’s correlations between message RNA expression of estrogen receptors and tumor necrosis factor-alpha, by disease and sex.

Spearman’s correlations
		Normal
		Females (n = 18)			Males (n = 18)			Together (n = 36)
		ESR1	ESR2	ESR1	ESR1	ESR2	ESR1	ESR1	ESR2	ESR1
				ESR2			ESR2			ESR2
ESR1	R value		0.01			-0.42			-0.19
	P value		0.9579			0.0861			0.2772
TNF-α	R value	0.05	0.54	-0.38	0.34	-0.11	0.35	0.2	0.18	0.01
	P value	0.8293	0.022a	0.119	0.1708	0.6508	0.16	0.2422	0.2972	0.9501
		HCV/cirrhosis
		Females (n = 15)			Males (n = 17)			Together (n = 32)
		ESR1	ESR2	ESR1	ESR1	ESR2	ESR1	ESR1	ESR2	ESR1
				ESR2			ESR2			ESR2
ESR1	R value		-0.84			0.57			-0.1
	P value		0.0002c			0.0197a			0.6038
TNF-α	R value	-0.3	0.64	-0.57	0.42	0.58	0.07	0.09	0.61	-0.19
	P value	0.2708	0.0116a	0.0286a	0.0934	0.0162a	0.802	0.6165	0.0002c	0.3017
		HCV/HCC
		Females (n = 5)			Males (n = 23)			Together (n = 28)
		ESR1	ESR2	ESR1	ESR1	ESR2	ESR1	ESR1	ESR2	ESR1
				ESR2			ESR2			ESR2
ESR1	R value		-0.1			0.14			0.08
	P value		0.95			0.5814			0.7301
TNF-α	R value	0	0.3	-0.1	-0.11	0.6	-0.56	-0.21	0.45	-0.57
	P value	> 0.99	0.6833	0.95	0.6627	0.0083b	0.0151a	0.3397	0.0293a	0.0049b

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

TNF-α: Tumor necrosis factor-alpha; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus.

ESR2 mRNA expression had a significant positive correlation with TNF-α in both HCV/cirrhosis (r = 0.61, P = 0.0002) and HCV/HCC patients (r = 0.45, P = 0.0293) (Table 5). When stratified by sex within each disease group, ESR2 was found to maintain the significant positive correlation with TNF-α in both HCV/cirrhosis males and females (r = 0.58, P = 0.0162; r = 0.64, P = 0.0116 respectively) but for HCV/HCC, only males had any significant correlation (r = 0.60, P = 0.0083) (Table 5). Interestingly, normal females also showed a significant positive correlation (r = 0.54, P = 0.0220). Despite the correlations found between ESR2 and TNF-α, the ratio of ESR1 to ESR2 was found to be correlated with TNF-α only in HCV/HCC patients (r = -0.57, P = 0.0049), but upon stratifying by sex, negative correlations were found between TNF-α and ESR1/ESR2 in HCV/HCC males (r = -0.56, P = 0.0151) and HCV/cirrhosis females (r = -0.57, P = 0.0286) (Table 5).

DISCUSSION

Chronic infection with HCV and the associated long-term inflammation causes affected individuals to be highly susceptible to liver complications such as fibrosis, cirrhosis, and HCC[34,35]. It is well established that male sex is a major risk factor for complications associated with chronic HCV infection[10,11,14,36,37]. Compared to females, males are three times more likely to develop liver cancer and four times more likely to die from cancer[38-40]. In HCC, estrogen has been shown to downregulate the production of key inflammatory markers as well as inhibit the activation of tumor-associated[41-43], which suggests that estrogen may directly contribute to the lower HCC incidence among females. However, there remains a huge gap in knowledge regarding the role of ER subtypes expression in HCV-associated disease, and the related contributions of inflammatory markers in these immune responses.

ERs play a pivotal role in modulating the immune system, particularly by influencing the behavior of macrophages and T cells, which are key players in immune responses. ERs are expressed on these immune cells and can modulate their functions in a ligand-dependent manner. In macrophages, estrogen signaling often results in an anti-inflammatory phenotype, reducing the secretion of pro-inflammatory cytokines like TNF-α and interleukin (IL)-6 while enhancing the release of anti-inflammatory cytokines like IL-10[20,44]. This modulation can create an environment that dampens excessive inflammation. Similarly, ERs on T cells influence their differentiation and activity; for instance, estrogen can promote the expansion of regulatory T cells, which help maintain immune tolerance, and modulate the activity of effector T cells, such as Th1 and Th17 cells, which are involved in inflammatory responses. In the context of HCV-related diseases, these estrogen-mediated effects could significantly impact disease progression. By reducing inflammation and promoting immune regulation, estrogen signaling might slow liver fibrosis and reduce the risk of cirrhosis or HCC[45,46]. Conversely, the immunosuppressive effects of estrogen might impair the clearance of HCV, potentially facilitating chronic infection. Understanding these dual roles highlights the complexity of estrogen's influence on immune responses in HCV-related diseases and underscores the need for tailored therapeutic approaches.

A major limitation of our study is due to the epidemiology of HCV-associated diseases; as previously stated, males are three times more likely to develop liver cancer compared to females. This results in a large discrepancy in our sample sizes between males and females, particularly in our HCC group (Table 2). Future studies should include more female patients as able, as well as a more diverse range of ethnicities, particularly individuals from Asian descent, so that the conclusions can be more broadly relevant.

Since ERβ was discovered more than a decade after ERα, there are limited data on the role of ERβ in the liver; however, the results from this study shows its importance in HCV pathogenesis. Previous work from our lab reported significantly increased expression of ESR2 mRNA in HCV-associated diseased livers compared to normal[24]. In contrast, Iavarone et al[47] reported a loss of ESR2 expression in patients with HCC compared to those with chronic liver disease. The present study found that while ESR2 mRNA expression was significantly lower in the HCV/HCC group compared to normals, cytoplasmic and nuclear protein expression was increased in both HCV/cirrhosis and HCV/HCC groups. The conflicting results observed at the translational level vs the transcriptional level may be attributed to the understanding that protein expression may not correspond linearly to its mRNA expression, due to possible disparities in translation efficiency or the half-life of the molecules[48]. Studies to further reveal the function of ERβ and its variants in HCV pathogenesis are warranted in order understand these differences in mRNA and protein expression.

Because all of the patient cases in this study were recipients of a liver transplant, it is important to understand the criteria to qualify for transplantation. Model for end-stage liver disease (MELD) scores are used to determine transplant candidacy in cirrhotic patients; in general, patients can qualify for liver transplantation once their MELD score is ≥ 15[49]. Patients with a MELD score < 15 may still become eligible if they have certain conditions or complications, such as HCC[49]. Patients with HCC can qualify for liver transplantation if they have either a single tumor ≤ 5 cm or up to three separate lesions all < 3 cm and no evidence of vascular invasion or metastasis. To summarize, in order to qualify for transplantation, the cirrhotic patients in our cohort needed to present with more advanced cirrhosis while the HCC patients were required to have less severe cancer. Furthermore, as our study only included patients with end-stage liver disease, we cannot draw conclusions regarding early disease pathways. In the future, samples from early stages of HCV-associated liver disease should be included to more comprehensively reveal the role that ERs play.

Expression of ERα is generally thought to promote carcinogenesis while ERβ acts as a tumor suppressor[50]; however, much of the work looking at ER expression in cancer has been in breast tissues. Furthermore, ER subtype expression can vary greatly depending on sex, age, disease conditions, and other variables. In our cohort, ESR2 transcript expression was greater than ESR1 expression in normal livers, and we also showed altered expression of ERβ, but not ERα, in patients with HCV-associated diseases. Our study was the first to report mRNA levels of ERα and ERβ in normal human livers from a United States population, and our results give evidence that ERβ may play a more important role than previous thought.

There is not yet a consensus on whether hepatic expression of either ER subtype is beneficial or detrimental in HCV pathogenesis. Some studies report a protective effect of ERα expression[51-53], others describe associations between ERα expression and worse prognosis[24], and still others report no correlations[54]. Although no significant differences in expression of ERα mRNA or protein was found in either HCV/cirrhosis or HCV/HCC groups compared to normals, it was determined that in this cohort, ESR1 is negatively correlated with AST and bilirubin (cirrhosis only) and with ALP (HCC only) (data not shown). These results support the conclusion that ESR1 expression is associated with better liver function. However, using primers/antibodies for only wild-type (wt) ERα and wtERβ only gives us partial data as there are several ER variants or isoforms with diverse tissue-specific expression patterns and functions. As liver function worsens, there is a decrease in wtERα expression and ERα variants (ERα46 and ERα36) are upregulated; this upregulation is associated with a worse prognosis for HCV-associated diseases[55-59]. In addition, this project only looked at the expression of markers in extratumoral tissues, as tumor biopsies were not available for all samples. Future work should include tumor samples from patients with HCC so that the role of ERs in the tumor microenvironment can be studied.

As expected, TNF-α expression levels were highest in cirrhosis and HCC livers, since these diseases are primarily driven by chronic inflammation and TNF-α is a potent proinflammatory cytokine. Notably, expression in HCC appears to be lower than in cirrhosis. This corresponds with other studies that reported a decrease in TNF-α protein expression in more advanced HCV-related disease[60]. Nevertheless, the role of TNF-α in HCV pathogenesis is decidedly complex.

Estrogen has been shown to be associated with a decrease in TNF-α expression[18,19,61], which is supported by an in vitro experiment we performed demonstrating that treatment with estradiol significantly downregulated expression of TNF-α mRNA in human hepatoma Huh7 cell line (data not shown). Estrogen downregulation of TNF-α may help explain the less severe disease presentation in females compared to males[62]. However, in human liver tissues, ESR2 was positively correlated with TNF-α in all disease/sex groups except for normal males and HCC females. While the lack of correlation in HCC females may be attributed to our small sample size (n = 5), the same cannot be said of the normal males. Although the correlation between ESR2 and TNF-α was demonstrated by our study, future studies should include in vitro models to further explore the functional mechanism.

In addition to looking at associations between ER subtypes and immune markers, another objective of the project was to investigate the relationship between hepatic ERα and ERβ and their distinctive roles in the liver. The relative expression of ERα and ERβ in a given environment is a significant determinant of their response to both endogenous and synthetic ligands, and a number of studies have observed ERβ-mediated modulation of ERα activity[63-67]. Upon binding with a ligand, ERs will dimerize prior to translocating to the nucleus, and relative concentrations of ERα and ERβ determine whether they will homodimerize or heterodimerize. ER homodimers regulate a different set of genes than that of ERαβ heterodimers[68].

These results as well as the data on TNF-α expression draw attention to the importance of considering time as a critical variable; in other words, the difference in outcomes may not be necessarily due to the distinct activity or interactions of the molecules, but rather in the regulation of immune pathways at different stages of HCV infection, namely fibrosis and HCC progression.

Genetics may very well play a role too; a polymorphism in a recently discovered type III interferon, IFNL4-ΔG/TT (rs368234815), has been strongly associated with HCV clearance and response to treatment[69]. Contrary to the typical antiviral function of interferons, it is individuals who carry the IFNL4-ΔG deletion allele, and therefore generate the full interferon-λ4 protein, who have impaired HCV clearance and response to treatment[69-72]. In the present study, we found that in patients with INFL4-ΔG/ΔG genotype, specifically female patients, hepatic expression of ESR2 was found to be significantly decreased (Supplementary Figure 1). This finding is consistent with the observation that ERβ expression is protective in some cancers[50]. Furthermore, we also found a positive correlation of ESR1 with ESR2 in cirrhosis males, and a negative correlation in cirrhosis females and IFNL4-ΔG allele females (data not shown). ESR1 and ESR2 or their isoforms are known to coregulate the activity of each other[73-76] and our results offer some evidence that coregulation may be, at least in part, dependent on sex.

This study further confirms the conclusion from our previous study[24] that differential ER subtype expression is observed in males and females in both the premalignant and malignant stages of HCV-related disease progression. Further research in other inflammatory, anti-inflammatory, and oncogenic markers is, therefore, an essential next step in elucidating the immunomodulation by ER subtypes in the liver. In addition, since the focus of this study was on nuclear ERα and β, more research is needed to determine if the sex-based differences in HCV infection outcome are also mediated G protein coupled estrogen receptor or by isoforms of the nuclear receptors.

Something that also needs to be considered is the possibility that while estrogen may have inherent protective functions, the differences in HCV pathogenesis and disease progression between males and females may be exacerbated by the inhibitory effects of testosterone and progesterone on immune response[77]. For that reason, evaluating the role of other sex steroids and the expression and function of their receptors would be a fruitful area for further work.

HCV remains a problem of scientific and clinical significance due to the genetic variability of the virus, lack of robust early detection methods, and challenges of vaccine development[78]. This project will be the basis for future work investigating the factors that are responsible for the sex-based differences in HCV disease pathogenesis. Studying the molecular pathways involved will lead to a better understanding of the reasons behind why only a fraction of individuals are able to clear the virus on their own, and will facilitate more personalized diagnosis and care.

CONCLUSION

Our study, for the first time, demonstrates an increase in expression of ERβ compared to ERα in the liver of normal males and females. In addition, ERβ mRNA expression was found to be decreased in HCV-positive livers, while TNF-α expression was increased. ERβ mRNA expression was also decreased in livers with the IFNL4-ΔG/ΔG genotype. Further analysis of the data revealed sex-specific correlations between ERα and ERβ. These findings suggest that changes in ERβ expression are associated with worsening HCV-related disease, and may be one of the sex-dependent factors in cirrhosis and HCC pathogenesis. Any changes in ER subtype ratio during progression of cirrhosis and cancer development in relation to TNF-α expression may provide crucial information especially in patients with IFNL4-ΔG/ΔG genotype. This information may also help us to monitor host therapeutic responses and viral clearance. Future studies can focus on signaling pathways in relation to ER subtype receptors that may intersect with TNF-α in the liver for development of sex-based novel therapeutics.

ACKNOWLEDGEMENTS

Much appreciation for the collaboration with Dr. Prokunina-Olsson L at the Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics (NCI/NIH, Bethesda, MD, United States).